vTv Therapeutics (VTVT) Cash & Equivalents (2014 - 2026)

vTv Therapeutics has disclosed Cash & Equivalents across 13 years of filings, most recently posting $98.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $98.1 million, up 215.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.1 million (up 215.81% YoY), and the FY2025 annual result was $88.9 million, up 142.02% from the prior year.
• Cash & Equivalents came in at $98.1 million for Q1 2026 at vTv Therapeutics, up from $88.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.5 million in Q3 2025 to a low of $8.2 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $25.9 million (2025), against an average of $36.8 million.
• Across the five-year window, Cash & Equivalents tumbled 46.54% in 2023 and jumped 406.96% in 2024, its largest moves.
• vTv Therapeutics' Cash & Equivalents stood at $12.1 million in 2022, then slipped by 22.1% to $9.4 million in 2023, then jumped by 289.01% to $36.7 million in 2024, then jumped by 142.02% to $88.9 million in 2025, then increased by 10.29% to $98.1 million in 2026.
• The last three Cash & Equivalents figures came in at $98.1 million (Q1 2026), $88.9 million (Q4 2025), and $98.5 million (Q3 2025), per Business Quant data.